Literature DB >> 23190154

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours.

César Serrano1, Sara Simonetti, Javier Hernández-Losa, Claudia Valverde, Cristina Carrato, Silvia Bagué, Ruth Orellana, Rosa Somoza, Teresa Moliné, Joan Carles, Pere Huguet, Cleofé Romagosa, Santiago Ramón y Cajal.   

Abstract

AIMS: Benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumours occur either sporadically or are related to neurofibromatosis (NF). The mechanisms involved are well known in NF-related tumours, but still remain unclear in sporadic cases. Somatic BRAF and KRAS mutations represent the most frequent genetic events in melanocytic neoplastic lesions. Because melanocytes and Schwann cells both derive from neural crest cells, we hypothesized that BRAF and KRAS mutations might influence BPNST and MPNST development. METHODS AND
RESULTS: BRAF exon 15 and KRAS exons 2 and 3 polymerase chain reaction (PCR) sequencing was performed in formalin-fixed/paraffin-embedded samples of 99 BPNST and MPNST, related and non-related to NF types 1 and 2. Oncogenic BRAF V600E mutations were found in four of 40 schwannomas (including one acoustic neuroma) and one of 13 MPNST, not associated with NF. A KRAS G12S mutation was also evident in one sporadic schwannoma.
CONCLUSION: Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an important event in a subset of peripheral nerve sheath tumours not related to NF.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190154     DOI: 10.1111/his.12021

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

1.  A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.

Authors:  Zhao-Hui Li; Xin-Min Pan; Bao-Wei Han; Xiao-Min Guo; Zhen Zhang; Jing Jia; Lin-Bo Gao
Journal:  Tumour Biol       Date:  2013-06-02

2.  Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.

Authors:  Santhosh A Upadhyaya; Rose B McGee; Breelyn A Wilky; Alberto Broniscer
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

3.  DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis.

Authors:  Barbara Rivera; Javad Nadaf; Somayyeh Fahiminiya; Maria Apellaniz-Ruiz; Avi Saskin; Anne-Sophie Chong; Sahil Sharma; Rabea Wagener; Timothée Revil; Vincenzo Condello; Zineb Harra; Nancy Hamel; Nelly Sabbaghian; Karl Muchantef; Christian Thomas; Leanne de Kock; Marie-Noëlle Hébert-Blouin; Angelia V Bassenden; Hannah Rabenstein; Ozgur Mete; Ralf Paschke; Marc P Pusztaszeri; Werner Paulus; Albert Berghuis; Jiannis Ragoussis; Yuri E Nikiforov; Reiner Siebert; Steffen Albrecht; Robert Turcotte; Martin Hasselblatt; Marc R Fabian; William D Foulkes
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  DGCR8 and the six hit, three-step model of schwannomatosis.

Authors:  Clara Nogué; Anne-Sophie Chong; Elia Grau; HyeRim Han; Eduard Dorca; Carla Roca; Jose Luis Mosquera; Conxi Lázaro; William D Foulkes; Joan Brunet; Barbara Rivera
Journal:  Acta Neuropathol       Date:  2021-11-25       Impact factor: 17.088

5.  BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.

Authors:  Angela C Hirbe; Melike Pekmezci; Sonika Dahiya; Anthony J Apicelli; Brian A Van Tine; Arie Perry; David H Gutmann
Journal:  Neuro Oncol       Date:  2013-12-22       Impact factor: 12.300

6.  TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.

Authors:  Hendrikus J Dubbink; Hannah Bakels; Edward Post; Ellen C Zwarthoff; Robert M Verdijk
Journal:  J Neurooncol       Date:  2014-07-18       Impact factor: 4.130

7.  Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.

Authors:  Aaron M Udager; Jincheng Pan; Martin J Magers; Ganesh S Palapattu; Todd M Morgan; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; David C Miller; James S Wolf; Jonathan B McHugh; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

Review 8.  From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.

Authors:  Kathryn M Lemberg; Jiawan Wang; Christine A Pratilas
Journal:  Genes (Basel)       Date:  2020-06-24       Impact factor: 4.096

Review 9.  BRAF mutation and its inhibitors in sarcoma treatment.

Authors:  Haotian Liu; Nahar Nazmun; Shafat Hassan; Xinyue Liu; Jilong Yang
Journal:  Cancer Med       Date:  2020-05-31       Impact factor: 4.452

10.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.

Authors:  Vivek Subbiah; Shannon N Westin; Kai Wang; Dejka Araujo; Wei-Lien Wang; Vincent A Miller; Jeffrey S Ross; Phillip J Stephens; Gary A Palmer; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2014-01-14       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.